Based on the Evaxion Biotech AS stock forecast from 1 analysts, the average analyst target price for Evaxion Biotech AS is USD 6.00 over the next 12 months. Evaxion Biotech AS’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Evaxion Biotech AS is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Evaxion Biotech AS’s stock price was USD 1.44. Evaxion Biotech AS’s stock price has changed by -22.16% over the past week, -23.40% over the past month and -92.96% over the last year.
No recent analyst target price found for Evaxion Biotech AS
No recent average analyst rating found for Evaxion Biotech AS
Company Overview Evaxion Biotech AS
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. Read Less
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine ...Read More
Frequently Asked Questions About Evaxion Biotech AS (EVAX) Stock
Based on ratings from 1 analysts Evaxion Biotech AS's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on EVAX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for EVAX is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on EVAX's stock to indicate if its overvalued.
The last closing price of EVAX's stock was USD 1.44.
The most recent market capitalization for EVAX is USD 0.01B.
Based on targets from 1 analysts, the average taret price for EVAX is projected at USD 6.00 over the next 12 months.
This means that EVAX's stock price may go up by +334.78% over the next 12 months.
We can't find any ETFs which contains Evaxion Biotech AS's stock.
As per our most recent records Evaxion Biotech AS has 49 Employees.
Evaxion Biotech AS's registered address is Dr. Neergaards Vej, Horsholm, Denmark, 2970.
You can get more information about it from Evaxion Biotech AS's website at https://evaxion.ai.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Evaxion Biotech AS (EVAX) Stock
Based on ratings from 1 analysts Evaxion Biotech AS's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on EVAX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for EVAX is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on EVAX's stock to indicate if its overvalued.
The last closing price of EVAX's stock was USD 1.44.
The most recent market capitalization for EVAX is USD 0.01B.
Based on targets from 1 analysts, the average taret price for EVAX is projected at USD 6.00 over the next 12 months.
This means that EVAX's stock price may go up by +334.78% over the next 12 months.
We can't find any ETFs which contains Evaxion Biotech AS's stock.
As per our most recent records Evaxion Biotech AS has 49 Employees.
Evaxion Biotech AS's registered address is Dr. Neergaards Vej, Horsholm, Denmark, 2970.
You can get more information about it from Evaxion Biotech AS's website at https://evaxion.ai.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EVAX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
